Risk Factors for Atrial Fibrillation After Lung Cancer Surgery: Analysis of The Society of Thoracic Surgeons General Thoracic Surgery Database

2010 ◽  
Vol 90 (2) ◽  
pp. 368-374 ◽  
Author(s):  
Mark Onaitis ◽  
Thomas D'Amico ◽  
Yue Zhao ◽  
Sean O'Brien ◽  
David Harpole
Surgery Today ◽  
2015 ◽  
Vol 46 (8) ◽  
pp. 877-886 ◽  
Author(s):  
Takekazu Iwata ◽  
Kaoru Nagato ◽  
Takahiro Nakajima ◽  
Hidemi Suzuki ◽  
Shigetoshi Yoshida ◽  
...  

2018 ◽  
Vol 44 (04) ◽  
pp. 334-340 ◽  
Author(s):  
Yu-ping Li ◽  
Lei Shen ◽  
Wei Huang ◽  
Xue-fei Hu ◽  
Dong Xie ◽  
...  

AbstractAcute pulmonary embolism (PE) is one of the serious complications with high mortality after thoracic surgery. The authors aimed to determine the prevalence of PE events and evaluate additional risk factors for PE in patients with lung cancer surgery. Patients underwent lung cancer resections during January 2012 to July 2015 and had 30-day postoperative follow-up were included. Those with incomplete or miscoded data were excluded. The number of postoperative PE events was recorded retrospectively. Analyses were used to evaluate risk factors of PE during the hospitalization. The authors reviewed 11,474 patients who underwent surgery for lung cancer. The overall 30-day incidence of PE after thoracic surgery at their institution was 0.53%. The 30-day PE incidence without chemical prophylaxis was 0.57% (55/9,726) and the mortality rate was 10%. Multivariate analyses revealed that age over 66 (odds ratio [OR]: 1.09, 95% confidence interval [CI]: 1.05–1.12, p < 0.001), more extensive surgery than lobectomy (OR: 2.34, 95% CI: 1.28–4.25, p = 0.006) and stage IV of lung cancer (OR: 4.22, 95% CI: 1.50–11.9, p = 0.007) were associated with an increased risk of PE. Using these additional risk factors, based on readily available clinical characteristics, can help to risk-stratify patients and warrant extended chemical prophylaxis for patients to reduce the incidence of acute PE.


Surgery Today ◽  
2016 ◽  
Vol 47 (2) ◽  
pp. 252-258 ◽  
Author(s):  
Yusuke Muranishi ◽  
Makoto Sonobe ◽  
Toshi Menju ◽  
Akihiro Aoyama ◽  
Toyohumi F. Chen-Yoshikawa ◽  
...  

Surgery Today ◽  
2021 ◽  
Author(s):  
Toshiki Takemoto ◽  
Junichi Soh ◽  
Shuta Ohara ◽  
Toshio Fujino ◽  
Takamasa Koga ◽  
...  

2018 ◽  
Vol 36 (23) ◽  
pp. 2378-2385 ◽  
Author(s):  
Daniel J. Boffa ◽  
Andrzej S. Kosinski ◽  
Anthony P. Furnary ◽  
Sunghee Kim ◽  
Mark W. Onaitis ◽  
...  

Purpose The prevalence of minimally invasive lung cancer surgery using video-assisted thoracic surgery (VATS) has increased dramatically over the past decade, yet recent studies have suggested that the lymph node evaluation during VATS lobectomy is inadequate. We hypothesized that the minimally invasive approach to lobectomy for stage I lung cancer resulted in a longitudinal outcome that was not inferior to thoracotomy. Patients and Methods Patients > 65 years of age who had undergone lobectomy for stage I lung cancer between 2002 and 2013 were analyzed within the Society of Thoracic Surgeons General Thoracic Surgery Database, which had been linked to Medicare data, as part of a retrospective-cohort, noninferiority study. Results A total of 10,597 patients with clinical stage I lung cancer who underwent lobectomy were evaluated (4,448 patients underwent thoracotomy, and 6,149 underwent VATS). VATS patients had a more favorable distribution of all health-related variables, including pulmonary function (59% of VATS patients had intact spirometry v 51% of thoracotomy patients; P < .001). Cox proportional hazards models were performed over two eras to account for an evolving practice standard. The mortality risk associated with the VATS approach was not greater than thoracotomy in either the earlier era (2002 to 2008; hazard ratio, 0.97; 95% CI, 0.87 to 1.09; P = .62) or the more recent era (2009 to 2013; hazard ratio, 0.84; 95% CI, 0.75 to 0.93; P < .001). Kaplan-Meier survival estimates of 2,901 propensity-matched VATS-thoracotomy pairs demonstrated that the 4-year survival associated with VATS (68.6%) was modestly superior to thoracotomy (64.8%; P = .003). The analyses detailed above were replicated in a separate cohort of pathologic stage I patients with similar findings. Conclusion The long-term efficacy of lobectomy for stage I lung cancer performed using the VATS approach by board-certified thoracic surgeons does not seem to be inferior to that of thoracotomy.


2015 ◽  
Vol 109 (10) ◽  
pp. 1340-1346 ◽  
Author(s):  
Dennis F. Simonsen ◽  
Mette Søgaard ◽  
Imre Bozi ◽  
Charles R. Horsburgh ◽  
Reimar W. Thomsen

2019 ◽  
Vol 28 (17) ◽  
pp. S16-S22
Author(s):  
Maureen King ◽  
Amy Kerr ◽  
Sandra Dixon ◽  
Sarah Taylor ◽  
Alison Smith ◽  
...  

Postoperative complications following curative lung cancer surgery are well recognised, but there is limited data on 30-day readmission rates. The UK Thoracic Surgery Group conducted a multicentre review over a 3-month period to assess readmission rates. Overall readmission among the 268 patients who had undergone primary lung cancer surgery was 30 (11%); 14/30 of readmissions occurred within 7 days of discharge, with 13/30 patients readmitted to a hospital that had not performed the surgery. The causes of readmission were mainly pulmonary related (16/30). Readmission was associated with being discharged with a pleural drain 11/30 (P<0.01), having two or more postoperative complications 11/30 (P<0.01) and a patient's readiness for discharge 9/30 (P=0.001). There was a trend toward an association with smoking 13/30 (P=0.18). The authors suggest that a greater focus on patients presenting with characteristics associated with readmission, and incorporating a patient's readiness for discharge, may reduce readmission, although more studies are needed.


Sign in / Sign up

Export Citation Format

Share Document